Marpa Minds expands Spravato access in Westchester and Rockland

Marpa Minds says it is expanding FDA-approved Spravato therapy for adults with treatment-resistant depression at its White Plains and Suffern clinics. The move aims to make specialized esketamine care more accessible across Westchester and Rockland counties, with insurance support and supervised treatment built into the program.

Why it matters: - Treatment-resistant depression can leave patients with limited options after traditional antidepressants fail. - Marpa Minds is broadening access to FDA-approved Spravato® therapy in two Hudson Valley locations, which could shorten the path to specialized care for more patients. - The clinic is bundling evaluation, insurance support and medically supervised treatment, which may reduce common barriers to starting esketamine therapy.

What happened: - Marpa Minds announced expanded access to Spravato® (esketamine) therapy for adults with treatment-resistant depression in Westchester and Rockland counties. - The outpatient psychiatric clinic operates in White Plains and Suffern, NY. - The program is REMS-certified and delivers treatment under the FDA's Spravato REMS requirements. - The expansion is aimed at patients whose depression has not responded to conventional antidepressants.

The details: - Spravato® is the first and only FDA-approved nasal spray for adults with treatment-resistant depression. - As of January 2025, Spravato® is FDA-approved both as a standalone treatment and alongside an oral antidepressant. - Marpa Minds says patients receive comprehensive psychiatric evaluations to determine whether Spravato® is appropriate. - The clinic team handles insurance verification and prior authorization before treatment begins. - Medically supervised treatment sessions are delivered at REMS-certified locations. - Patients also receive follow-up care and treatment planning based on response and long-term goals. - The clinical team tailors treatment recommendations to each patient's symptoms, history and mental health goals. - The program is led by Dr. Benjamin Medrano, MD, Practice Owner and Medical Director. - Amy Della Rocca, MSN, MPH, PMHNP-BC, serves as Clinical Director and has overseen thousands of Spravato® and ketamine treatment sessions. - Marpa Minds also offers IV and IM ketamine therapy, TMS therapy and IV nutrient therapy. - The clinic serves patients in Westchester County, Rockland County, Bergen County, NJ, and surrounding communities. - Patients can schedule a consultation by calling +1 (914) 577-7646 or visiting the clinic's website. - Marpa Minds listed its social channels on LinkedIn, Instagram, Facebook, YouTube and Apple Podcasts.

Between the lines: - The announcement positions Marpa Minds as a more integrated access point for esketamine care, rather than a clinic focused only on treatment delivery. - The emphasis on REMS certification, insurance navigation and individualized planning suggests the clinic is trying to lower friction in a therapy that typically requires multiple clinical and administrative steps. - Mentioning multiple treatment options signals a broader depression-care model that can sequence or combine therapies based on patient need.

What's next: - Patients interested in Spravato® will need a consultation to determine eligibility. - Marpa Minds is likely to continue steering patients through evaluation, authorization and supervised treatment as demand for nontraditional depression therapies grows. - The clinic may use its White Plains and Suffern locations to draw patients from both sides of the Hudson Valley and nearby New Jersey.